The Dow Jones Industrial Average and other major indexes fell Monday afternoon as investors sold holdings in this ...

Shares of Ultragenyx and Mereo BioPharma were rocked by disappointing late-stage trial results of their brittle-bone disease treatment. It's looking like a poor end to 2025 for investors in two ...

On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ...

Investing.com -- Mereo BioPharma Group plc (NASDAQ:MREO) stock plunged 90.3% on Monday after the company announced that its Phase 3 clinical trials for setrusumab in Osteogenesis Imperfecta failed to ...

Mereo Biopharma Group Plc ( ($MREO) ) has shared an announcement. On December 29, 2025, Mereo BioPharma reported that its Phase 3 ORBIT and COSMIC ...

Ultragenyx Pharmaceutical and Mereo BioPharma said their two Phase 3 trials for setrusumab to treat rare bone disorder osteogenesis imperfecta, didn't meet their main goal of reducing fracture rates.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) tumbled 43.7% to $19.26 in pre-market trading after the company and its partner ...

As of September 30, the fund reported holding nearly 1.7 million Teva shares valued at $34.13 million. These 10 stocks could mint the next wave of millionaires › Prague-based Pale Fire Capital SE ...

Chevron (CVX) faces subdued dividend growth due to lower oil prices. See which stocks may offer higher increases and insights ...

Veeva Systems Inc. is downgraded to Hold with reduced price target of $236, reflecting limited upside from current levels.

Here are some of the stocks making notable moves in Friday's premarket action: Biohaven shares tumbled 15% after the biopharmaceutical company said Wednesday that [a Phase 2 study of its treatment for ...

Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular in the first mo | Of the top 10 biopharma M&A deals of 2025, six ...